Zhuhai Trinomab Company Profile - aVenture Research
Zhuhai Trinomab
Trinomab's platform makes fully human monoclonal antibodies replacing blood-derived immunoglobulin products; Siltartoxatug Injection is its first China-approved commercial product.
Zhuhai Trinomab is an antibody drug developer whose platform aids discovery and production of fully human monoclonal antibodies and supplies products and pipeline. Approved products are Siltartoxatug Injection, its first commercial product approved in China, and Retavibart Injection, previously TNM001, approved for marketing in China. Pipeline has TNM005, an in-house fully human antibody against varicella-zoster virus; TNM006, an in-house intravenous fully human antibody against human cytomegalovirus; TNM035, an in-house fully human antibody binding dengue virus E protein.
For adults, Siltartoxatug is indicated for emergency prevention of tetanus. One injection without weight-based dosing is said to cover a full RSV season. Prior to Siltartoxatug, clinicians used blood products as passive immune preparations against tetanus, and Siltartoxatug serves as an alternative to those blood-derived passive immune preparations.
